Review Article
Research progression of blood and fecal metabolites in colorectal cancer
Authors:
Cheng Kong,
Department of GI Surgery, Shanghai Tenth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai, CN
About Cheng
MD
Renyuan Gao,
Department of GI Surgery, Shanghai Tenth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai, CN
About Renyuan
MD
Xuebing Yan,
Department of GI Surgery, Shanghai Tenth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai, CN
About Xuebing
MD
Huanlong Qin
Department of GI Surgery, Shanghai Tenth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai, No. 301 Middle Yanchang Road, Jingan District, 200072, CN
About Huanlong
MD, PhD
Abstract
The development of colorectal cancer (CRC) is correlated with metabolic changes, suggesting great potential of metabolites to be diagnostic and prognostic biomarkers for clinical management. A large variety of metabolites have recently been identified due to their oncogenic role and clinical significance. Although the resultsmay vary within studies due to their diversity and complexity, these biomarkers profoundly reflecting intestinal homeostasis and disease status can be further developed as noninvasive diagnostic tools in complementary to traditional approaches such as colonoscopy, particularly for early population-based screening. This review focuses on the potential clinical utilities of metabolites as novel biomarkers in CRC, and discusses the metabolites-directed strategy for early diagnosis.
How to Cite:
Kong C, Gao R, Yan X, Qin H. Research progression of blood and fecal metabolites in colorectal cancer. International Journal of Surgery: Oncology. 2017;3(1):e51. DOI: http://doi.org/10.1097/IJ9.0000000000000051
Published on
12 Dec 2017.
Peer Reviewed
Downloads
